Your browser doesn't support javascript.
loading
ER-mediated anti-tumor effects of shikonin on breast cancer.
Yang, Yang; Gao, Wenya; Tao, Shiying; Wang, Yanxia; Niu, Jianzhao; Zhao, Piwen; Rao, Chenchen; Yang, Lei.
Afiliação
  • Yang Y; School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.
  • Gao W; School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.
  • Tao S; School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China. Electronic address: taoshiying@bucm.edu.cn.
  • Wang Y; Dongzhimen Hospital Affiliated with Beijing University of Chinese Medicine, Beijing, 100029, China.
  • Niu J; School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.
  • Zhao P; School of Life Sciences, Beijing University of Chinese Medicine, Beijing, 100029, China.
  • Rao C; School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.
  • Yang L; Dongfang Hospital Affiliated with Beijing University of Chinese Medicine, Beijing, 100029, China.
Eur J Pharmacol ; 863: 172667, 2019 Nov 15.
Article em En | MEDLINE | ID: mdl-31545985
Estrogen receptor (ER) is expressed in most Breast cancer (BC) patients. G protein-coupled estrogen receptor (GPER), which is a membrane-bound estrogen receptor, is associated with the tumor development and progression in BC. Shikonin (SK) is a natural compound that is known to have anti-tumor effects. This study aims to assess the effects of shikonin on the cell proliferation, cell cycle and cell apoptosis of BC and whether the effects are related to ER/GPER signaling pathway. The results demonstrated that shikonin inhibited the cellular proliferation of MCF-7 BC cells via G0/G1 arrest and apoptosis in concentration-dependent manner. The anti-proliferative effect of SK on SK-BR-3 BC cells was associated with apoptosis. Both ERα and GPER were expressed in MCF-7 cells, while ERα were negative and GPER were positive in SK-BR-3 cells. Furthermore, shikonin downregulated the expression of ERα and GPER, and this effect was not affected by the estrogen environment. In addition, shikonin downregulated the EGFR and p-ERK expression in MCF-7 and SK-BR-3, which was also not affected by the estrogen environment. EGFR and p-ERK were still suppressed by co-treatment with the selective GPER against G1 or antagonist G15. In conclusion, these results suggest that shikonin shows anti-tumor effects on MCF-7 and SK-BR-3 cells. The effects seem to be associated with EGFR/p-ERK downregulation via ERα and GPER inhibition.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Naftoquinonas / Receptor alfa de Estrogênio / Receptor beta de Estrogênio / Antineoplásicos Idioma: En Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Naftoquinonas / Receptor alfa de Estrogênio / Receptor beta de Estrogênio / Antineoplásicos Idioma: En Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China